# Synaffix and Sotio Biotech sign $740M ADC licensing deal

Synaffix, a Lonza subsidiary, has signed a licensing deal with Sotio Biotech worth up to $740 million, allowing Sotio to use Synaffix's ADC technology for one bioconjugate program, with potential expansion to two more.

- Type: Contract
- Announced: 2023-10-16
- Where: Netherlands
- Value: $740.0M
- Status: announced
- Products: ADC technology, bioconjugate
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Lonza Group AG](https://endata.com/companies/20735.md) (investor)
- [Synaffix](https://endata.com/companies/73530.md) (supplier)
- [Sotio Biotech](https://endata.com/companies/73531.md) (customer)

## Sources

- [endpoints.news](https://endpoints.news/synaffix-locks-740m-adc-licensing-deal-with-sotio-plans-expansion-after-lonza-acquisition/), 2023-10-16: "Lonza’s Synaffix is adding another manufacturing licensing partnership by securing a $740 million deal with Sotio Biotech, which would allow Sotio to use the Dutch company’s three-pronged ADC tech."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.